CEACAM5 and neoplasm: Cibisatamab is the first T-cell bispecific antibody consisting of a 2-to-1 format, optimised for safety and efficacy, directly binding tumour cells via CEA and T cells via CD3; resulting in increased T-cell infiltration, T-cell activation and tumour-cell killing.